Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel gene control therapies. Founded in 2015 and headquartered in Cambridge, Massachusetts, Syros applies its proprietary gene control platform to uncover and modulate the expression of disease‐driving genes. The company’s approach aims to address the underlying genetic mechanisms of cancer and rare diseases, rather than merely treating symptoms.
Syros’s lead program, tamibarotene (SY-1425), is being evaluated in acute myeloid leukemia and other high‐need oncology indications, building on the compound’s selective retinoic acid receptor agonist properties. In addition to its oncology efforts, Syros is advancing preclinical and early‐stage programs targeting rare genetic disorders, leveraging insights from enhancer biology to develop therapies for conditions with limited treatment options.
With research operations centered in the United States, Syros collaborates with academic institutions and industry partners in Europe and Asia to accelerate its development timeline. The company maintains a strong intellectual property portfolio and has secured strategic alliances that bolster its ability to translate scientific discoveries into clinical candidates.
Under the leadership of President and Chief Executive Officer Nancy Simonian, Syros has built a multidisciplinary team of geneticists, molecular biologists, and clinical development experts. The company’s management team also includes seasoned professionals in regulatory affairs, medical affairs, and finance, all working to advance Syros’s mission of bringing first‐in‐class gene control medicines to patients.
AI Generated. May Contain Errors.
Free SYRS Stock Alerts